Compounds, methods of preparation and use thereof for treating cancer
AssigneeHong Kong Baptist University
InventorsHongxi XU, Zhengxiang XIA, Yuanzhi LAO, Hongsheng TAN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Kaixian CHEN, Albert Sun-Chi CHAN
Life of this patent
Estimating the term…
Abstract
The present invention provides two compounds, namely Compound A and B, as the potential anticancer drug, and a composition comprising said Compound A and/or B for treating cancer or tumor related diseases. The present invention also relates to methods of preparing the compounds from a natural source and a composition comprising the compounds, and using the same for treating cancer or tumor related diseases.
Claims17
A composition for treating cancer or tumor related diseases comprising an effective amount of xanthone derivatives having a formula of A or B as follows:
- or a mixture thereof.
A method for treating cancer or tumor related diseases by administering an effective amount of a composition to a subject in needs thereof, said composition comprising xanthone derivatives having a formula A or B as follows:
- or a mixture thereof.
A method of preparing a composition including xanthone derivatives having a formula of A or B as follows:
- or a mixture thereof, said method comprising:
- a) pulverizing leaves of Garcinia nujiangensis followed by extraction with acetone at room temperature for at least one time to yield an acetone-soluble extract;
- b) suspending the acetone-soluble extract in hot water followed by extraction with CH2Cl2 to yield a CH2Cl2-soluble fraction;
- c) subjecting the CH2Cl2-soluble fraction to a silica gel column followed by elution with a gradient of CH2Cl2/MeOH (1:0, 0:1) to afford at least seven fractions according to TLC monitor;
- d) a first fraction of the at least seven fractions collected from (c) is chromatographed on a column of silica gel eluted successively with a gradient of petroleum ether/ethyl acetate (3:1) to give at least four sub-fractions;
- e) one of the at least four sub-fractions is further separated by octadesylsilane with methyl alcohol/water (9:1) and purified by semipreparative HPLC with methyl alcohol/water (93:7) which contains 0.1% Trifluoroacetic acid.
Dependencies are inferred from the claim text.